Posts by Elizabeth Louise Hohmann, MD
-
Encapsulated Fecal Microbiota Transplantation Alters Gut Microbiome in Adults with Obesity
In a randomized, placebo-controlled trial, fecal microbiota transplantation administered via capsules sustainably altered gut microbiome composition in adults with obesity, but there were no significant changes in most metabolic markers.
-
Early Results of Remdesivir Trial Are Promising, But More Research Needed
For the first time, a double-blind, placebo-controlled clinical trial testing the antiviral drug remdesivir for treatment in COVID-19 has produced positive results. Mass General researchers say preliminary data from from the trial found that both the recovery time and mortality rate were lower in the treatment group.
-
Mass General First in New England to Enroll Patients in Remdesivir Clinical Trial for COVID-19
The hospital announces that the Infectious Disease Division has started enrolling patients in an international study of the antiviral drug, Remdesivir, which aims to treat those with the novel coronavirus (COVID-19).
-
Fecal Microbiota Transplant Cures Most Patients with C. Difficile Who Also Have Cirrhosis
Patients with cirrhosis who have recurrent or refractory Clostridium difficile infection are likely to be cured with oral frozen fecal microbiota transplant but may need more capsules than noncirrhotic patients do.
Biography
Dr. Hohmann is the physician director of the Partners Human Research Committees (IRBs) and staff physician in the Infectious Diseases Division at Massachusetts General Hospital.
Digestive Healthcare at Mass General
The Massachusetts General Hospital Digestive Healthcare Center is a collaborative practice of gastroenterologists, endoscopists, surgeons, radiologists, pathologists, hepatologists, oncologists and radiation oncologists dedicated to the prevention, diagnosis, treatment and management of digestive diseases.